Survival Analysis
Objective: Measurement of survival duration in transgenic mice treated with coenzyme Q10 and/or remacemide to evaluate therapeutic effects in Huntington's disease models
This is a Survival Analysis protocol using mouse as the model organism. The procedure involves 5 procedural steps, 1 equipment items, 2 materials. Extracted from a 2002 paper published in Journal of Neuroscience.
Model and subjects
mouse • R6/2 transgenic and N171-82Q transgenic • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Animal treatment initiation • Monitor survival duration • Monitor motor deficits and weight loss
Primary readouts
- Survival duration
- Development of motor deficits
- Weight loss
- Cerebral atrophy
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Animal treatment initiation
Administer coenzyme Q10 and/or remacemide orally to transgenic mice
Note: Treatment groups included: coenzyme Q10 alone, remacemide alone, and combined coenzyme Q10 and remacemide
View evidence from paper
“oral administration of either coenzyme Q10 or remacemide significantly extended survival and delayed the development of motor deficits”
Monitor survival duration
Track and record survival time in treated R6/2 and N171-82Q transgenic mice
Note: Combined treatment resulted in approximately 32% increase in survival in R6/2 mice and 17% increase in N171-82Q mice
View evidence from paper
“combined treatment, using coenzyme Q10 and remacemide together, was more efficacious than either compound alone, resulting in a ~32 and 17% increase in survival in the R6/2 and N171-82Q mice, respectively”
Monitor motor deficits and weight loss
Assess development of motor deficits and weight loss as secondary outcome measures
Note: Treatment delayed development of these symptoms
View evidence from paper
“delayed the development of motor deficits, weight loss, cerebral atrophy, and neuronal intranuclear inclusions”
Assess cerebral atrophy and neuronal inclusions
Evaluate cerebral atrophy and neuronal intranuclear inclusions in treated mice
Note: Treatment delayed development of these pathological features
View evidence from paper
“delayed the development of motor deficits, weight loss, cerebral atrophy, and neuronal intranuclear inclusions”
Perform magnetic resonance imaging
Conduct MRI scans to measure ventricular enlargement in vivo
Note: Combined treatment significantly attenuated ventricular enlargement
View evidence from paper
“Magnetic resonance imaging showed that combined treatment significantly attenuated ventricular enlargement in vivo”